Bleakley Financial Group LLC Grows Position in Zoetis Inc. (NYSE:ZTS)

Bleakley Financial Group LLC boosted its stake in Zoetis Inc. (NYSE:ZTSFree Report) by 15.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 12,351 shares of the company’s stock after acquiring an additional 1,612 shares during the period. Bleakley Financial Group LLC’s holdings in Zoetis were worth $2,012,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. AMF Tjanstepension AB boosted its position in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. CWM LLC lifted its stake in Zoetis by 1.8% during the third quarter. CWM LLC now owns 19,330 shares of the company’s stock worth $3,777,000 after purchasing an additional 339 shares in the last quarter. Wedmont Private Capital boosted its position in shares of Zoetis by 15.1% during the third quarter. Wedmont Private Capital now owns 2,958 shares of the company’s stock worth $554,000 after buying an additional 388 shares during the period. Quotient Wealth Partners LLC grew its stake in shares of Zoetis by 15.6% in the third quarter. Quotient Wealth Partners LLC now owns 3,562 shares of the company’s stock valued at $696,000 after buying an additional 480 shares in the last quarter. Finally, Pinnacle Bancorp Inc. raised its holdings in shares of Zoetis by 8.6% in the 3rd quarter. Pinnacle Bancorp Inc. now owns 3,595 shares of the company’s stock valued at $702,000 after buying an additional 285 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $171.37 on Friday. The firm has a market capitalization of $77.32 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 2.72 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s fifty day moving average price is $169.34 and its 200 day moving average price is $179.28. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. upped their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $215.00.

Check Out Our Latest Analysis on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.